Pharmacokinetics/pharmacodynamics of bisphosphonates: Use for optimisation of intermittent therapy for osteoporosis

Clinical Pharmacokinetics

Volumn 44, Issue 6, 2005, Pages 551-570

  Cremers, Serge C L M ^a   Pillai, Goonaseelan ^b   Papapoulos, Socrates E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

BLOOD ANALYSIS; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; FRACTURE; GAS CHROMATOGRAPHY; GASTROINTESTINAL ABSORPTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOTOPE LABELING; KIDNEY CLEARANCE; MASS SPECTROMETRY; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATIENT SATISFACTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIMULATION; URINALYSIS; URINARY EXCRETION;

ANIMALS; CLINICAL TRIALS; DIPHOSPHONATES; HUMANS; OSTEOPOROSIS;

EID: 22244432201     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200544060-00001     Document Type: Review

References (109)

1. Blomen LJMJ. History of the bisphosphonates: discovery and history of the non-medical uses of bisphosphonates. In: Bijvoet OLM, Fleisch H, Canfield RE, et al., editors. Bisphosphonates on bone. Amsterdam: Elsevier, 1995: 111-24
2. Fleisch H, Russell RGG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969; 165: 1262-4
3. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19 (1): 80-100
4. Consensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993; 94: 646-50
5. Melton III LJ, Cooper C. Magnitude and impact of osteoporosis and fractures. In: Marcus R, Feldman D, Kelsey J, editors. Osteoporosis. 2nd ed. New York: Academic Press, 2001: 557-77
6. Harris AL, Watts DJ, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282 (14): 1344-52
7. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-41
8. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 1998; 280 (24): 2077-82
9. McClung M, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344 (5): 333-40
10. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11 (1): 83-91
11. Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II: meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002; 23 (4): 508-16
12. Cranney A, Tugwell P, Adachi J, et al. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2003; 23 (4): 517-23
13. Bone HG, Adami S, Rizzoli R, et al. Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther 2000; 22 (1): 15-28
14. Greenspan SL, Bone III G, Schnitzer TJ, et al. Two-year results of once-weekly administration of alendronate 70mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002; 17 (11): 1988-96
15. Schnitzer T, Bone HG, Crepaldi G. Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000; 12: 1-12
16. Brown JP, Kenler DL, Mcclung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002; 71: 103-11
17. Chestnut III CH, Skag A, Christiansen C. Oral ibandronate osteoporosis vertebral fracture trial in North America and Europe (BONE): effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19 (8): 1241-9
18. Sparidans RW, Den Hartigh J. Chromatographic analysis of bisphosphonates. Pharm World Sci 1999; 21 (1): 1-10
19. Cremers S, Sparidans R, Den HJ, et al. A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. Eur J Clin Pharmacol 2002; 57: 883-90
20. Legay F, Gauron S, Deckert F, et al. Development and validation of a highly sensitive RIA for zoledronic acid, a new potent heterocyclic bisphosphonate, in human serum, plasma and urine. J Pharm Biomed Anal 2002; 30: 897-911
21. Phipps R, Lindsay R, Burgio D, et al. Head-to-head comparison of risedronate and alendronate pharmacokinetics at clinical doses. Bone 2004; 34: S81-S82
22. Makler PT, Charkes ND. Studies of skeletal tracer kinetics IV. optimum time delay for Tc-99m (Sn) methylene diphosphonate bone imaging. J Nucl Med 1980; 21: 641-5
23. Pillai G, Gieschke R, Goggin T, et al. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. Br J Clin Pharmacol 2004; 58 (6): 618-31
24. Mele M, Conte E, Fratello A, et al. Computer-analysis of Tce-99m DPD and Tc-99m MDP kinetics in human: concise communication. J Nucl Med 1983; 24: 334-8
25. Porras AG, Holland SD, Gertz BJ. Pharmacokinetics of alendronate. Clin Pharmacokinet 1999; 36 (5): 315-28
26. O'Flaherty EJ. Physiologically based models for bone-seeking elements. IV: Kinetics of lead disposition in humans. Toxicol Appl Pharmacol 1993; 118: 16-29
27. Mitchell DY, Barr WH, Eusebio RA, et al. Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration. Pharm Res 2001; 18 (2): 166-70
28. Hernandez CJ, Beaupre GS, Marcus R, et al. Long-term predictions of the therapeutic equivalence of daily and less than daily alendronate dosing. J Bone Miner Res 2002; 17 (9): 1662-6
29. Berenson JR, Ravera C, Ma P, et al. Population pharmacokinetics of zoledronate [abstract]. Proc Am Soc Clin Oncol 2002; 23: 209A
30. Chen T, Berenson JR, Vescio R, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002; 42 (11): 1228-36
31. Fogelman I, Bessent RG, Turner JG, et al. The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med 1978; 19 (3): 270-5
32. Hyldstrup L, Mogensen N, Finn-Jensen G, et al. Urinary 99mTc-diphosphonate excretion as a simple method to quantify bone metabolism. Scand J Clin Lab Invest 1984; 44: 105-9
33. Masarachia P, Weinreb M, Balena R, et al. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rate and mouse bones. Bone 1996; 19 (3): 281-90
34. Azuma Y, Sato H, Oue Y, et al. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 1995; 16 (2): 235-45
35. Sato M, Grasser W, Endo N, et al. Bisphosphonate action, alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88: 2095-105
36. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18 (2): 75-85
37. Powell JH, DeMark BR. Clinical pharmacokinetics of diphosphonates. In: Garattini S, editor. Bone resorption, metastasis and diphosphonates. New York: Raven Press, 1985; 41-9
38. Fogelman I, Smith L, Mazess R, et al. Absorption of oral diphosphonate in normal subjects. Clin Endocrinol (Oxf) 1986; 24 (1): 57-62
39. Kasting GB, Francis MD. Retention of etidronate in human, dog, and rat. J Bone Miner Res 1992; 7 (5): 513-22
40. Twiss IM, Burggraaf J, Schoemaker RC, et al. The sugar absorption test in the evaluation of the gastrointestinal intolerance to bisphosphonates: studies with oral pamidronate. Clin Pharmacol Ther 2001 Jun; 69 (6): 431-7
41. Hyldstrup L, Flesch G, Hauffe SA. Pharmacokinetic evaluation of pamidronate after oral administration: a study on dose proportionality, absolute bioavailability, and effect of repeated administration. Calcif Tissue Int 1993; 53 (5): 297-300
42. Berenson JR, Rosen L, Vescio R, et al. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 1997; 37 (4): 285-90
43. Leyvraz S, Hess U, Flesch G, et al. Pharmacokinetics of pamidronate in patients with bone metastases. J Natl Cancer Inst 1992; 84 (10): 788-92
44. Redalieu E, Coleman JM, Chan K, et al. Urinary excretion of aminohydroxypropylidene bisphosphonate in cancer patients after single intravenous infusions. J Pharm Sci 1993; 82 (6): 665-7
45. Dodwell DJ, Howell A, Morton AR, et al. Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia. Postgrad Med J 1992; 68 (800): 434-9
46. Daley-Yates PT, Dodwell DJ, Pongchaidecha M, et al. The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. Calcif Tissue Int 1991; 49 (6): 433-5
47. Yakatan GJ, Poynor WJ, Talbert RL, et al. Clodronate kinetics and bioavailability. Clin Pharmacol Ther 1982; 31 (3): 402-10
48. Castren-Kortekangas P, Loyttyniemi E, Liukko-Sipi S, et al. Pooling of clodronate urinary excretion data: a new pharmacokinetic method to study drugs with highly variable gastrointestinal absorption. J Bone Miner Res 1997; 12 (1): 66-71
49. Saha H, Castren-Kortekangas P, Ojanen S, et al. Pharmacokinetics of clodronate in renal failure. J Bone Miner Re. 1994; 9 (12): 1953-8
50. Saha HH, Ala-Houhala IO, Liukko-Sipi SH, et al. Pharmacokinetics of clodronate in peritoneal dialysis patients. Perit Dial Int 1998; 18 (2): 204-9
51. Hanhijarvi H, Elomaa I, Karlsson M, et al. Pharmacokinetics of disodium clodronate after daily intravenous infusions during five consecutive days. Int J Clin Pharmacol Ther Toxicol 1989; 27 (12): 602-6
52. Pentikainen PJ, Elomaa I, Nurmi AK, et al. Pharmacokinetics of clodronate in patients with metastatic breast cancer. Int J Clin Pharmacol Ther Toxicol 1989; 27 (5): 222-8
53. Ylitalo P, Holli K, Monkkonen J, et al. Comparison of pharmacokinetics of clodronate after single and repeated doses. Int J Clin Pharmacol Ther 1999; 37 (6): 294-300
54. Cocquyt V, Kline WF, Gertz BJ, et al. Pharmacokinetics of intravenous alendronate. J Clin Pharmacol 1999; 39 (4): 385-93
55. Khan SA, Kanis JA, Vasikaran S, et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997; 12 (10): 1700-7
56. Gertz BJ, Holland SD, Kline WF, et al. Studies on the oral bioavailability of alendronate. Clin Pharmacol Ther 1995; 58 (3): 288-98
57. Porras AG, Kline W, Dilzer S, et al. Oral bioavailability of alendronate 35- and 70-mg tablets [abstract]. Clin Pharmacol Ther 2001; 69 (2): P84
58. Mitchell DY, Eusebio RA, Sacco-Gibson NA, et al. Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. J Clin Pharmacol 2000; 40: 258-65
59. Mitchell DY, Eusebio RA, Dunlap LE, et al. Risedronate gastrointestinal absorption is independent of site and rate of administration. Pharm Res. 1998; 15 (2): 228-32
60. Mitchell DY, St Peter JV, Eusebio RA, et al. Effect of renal function on risedronate pharmacokinetics after a single oral dose. Br J Clin Pharmacol 2000; 49 (3): 215-22
61. Mitchell DY, Thompson GA, Eusebio RA, et al. Risedronate pharmacokinetics upon multiple dose administration to post-menopausal women for six months [abstract]. Clin Pharmacol Ther 1999; 65 (2): P189
62. Dooley M, Balfour JA. Ibandronate. Drugs 1999; 57 (1): 101-8
63. Bergner R, Dill K, Boerner D, et al. Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study. Nephrol Dial Transplant 2002; 17 (7): 1281-5
64. Neugebauer G, Hagena CH, Sakalova A, et al. Pharmacokinetics of ibandronate, a highly potent antiresorptive drug on bone metabolism in patients with multiple myeloma [abstract]. Eur J Clin Pharmacol 1998; 54 (6): A18
65. Ravn P, Neugebauer G, Christiansen C. Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone 2002; 30 (1): 320-4
66. Skerjanec A, Berenson J, Hsu C, et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 2003; 43: 154-62
67. Sansom LN, Necciari J, Thiercelin JF. Human pharmacokinetics of tiludronate. Bone. 1995; 17 (5 Suppl.): 479-83S
68. Schwietert HR, Peeters PA, Dingemanse J, et al. Multiple dose pharmacokinetics of tiludronate in healthy volunteers. Eur J Clin Pharmacol 1996; 51 (2): 175-81
69. Degrossi OJ, Ortiz M, Degrossi EB, et al. Serum kinetics, bioavailability and bone scanning of 99mTc-labelled sodium olpadronate in patients with different rates of bone turnover. Eur J Clin Pharmacol 1995; 48 (6): 489-94
70. Cremers SC, Eekhoff ME, Den Hartigh J, et al. Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone. J Bone Miner Res 2003; 18 (5): 868-75
71. Mitchell DY, Heise MA, Pallone KA, et al. The effect of dosing regimen on the pharmacokinetics of risedronate. Br J Clin Pharmacol 1999; 48 (4): 536-42
72. Van Beek E, Hoekstra M, van de Ruit M, et al. Structural requirements for bisphosphonate action in vitro. J Bone Miner Res 1994; 9 (12): 1875-82
73. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21 (2): 115-37
74. Parfitt AM, Mundy GR, Roodman GD, et al. A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res 1996; 11 (2): 150-9
75. Papapoulos SE. Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In: Marcus R, Feldman D, Kelsey J, editors. Osteoporosis. 1st ed. London: Academic Press, 1996: 1209-34
76. Rogers MJ, Frith JC, Luckman SP, et al. Molecular mechanisms of action of bisphosphonates. Bone 1999; 24 (5): 73-9S
77. Rodan GA. Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol 1998; 38: 375-88
78. Qvist P, Christgau S, Pedersen BJ, et al. Circadian variation in the serum concentration of C-terminal telopeptide of type 1 collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 2002; 31 (1): 57-61
79. Green JR, Mueller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9: 745-51
80. Major P, Lortholarly A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19 (2): 558-67
81. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001 Feb; 296 (2): 235-42
82. Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70mg compared with once-weekly risedronate 35mg in women with postmenopausal osteo-porosis: a randomized double-blind study. J Bone Miner Res 2005; 20 (1): 141-51
83. Papapoulos SE. Pharmacodynamics of bisphosphonates: implications for treatment. In: Bijvoet OLM, Fleisch HA, Canfield RE, et al., editors. Bisphosphonate on bones. Amsterdam: Elsevier Science BV, 1995: 231-45
84. McCloskey EV, Selby P, Davies M, et al. Oral clodronate significantly reduces fracture risk in women with post-menopausal or secondary osteoporosis [abstract]. J Bone Miner Res 2000; 15 Suppl. 1: S227
85. Brumsen C, Papapoulos SE, Lips P, et al. Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res 2002; 17 (6): 1057-64
86. Thiebaud D, Burckhardt P, Kriegbaum H, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997; 103 (4): 298-307
87. Riis BJ, Ise J, von Stein T, et al. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 2001; 16 (10): 1871-8
88. Cooper C, Emkey RD, McDonald RH, et al. Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003; 88 (10): 4609-15
89. Recker R, Stakkestad JA, Chesnut CH 3rd, et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004; 34 (5): 890-9
90. Adami S, Felsenberg D, Christiansen C, et al. Efficacy and safety of ibandronate given by intravenous injection every 3 months. Bone 2004; 34 (5): 881-90
91. Reid IR, Brown J, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346 (9): 653-61
92. Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003; 18 (3): 1051-6
93. Papapoulos SE. Pharmacological management of Paget's distease of bone. Clin Rev in Bone Miner Metab 2002; 1: 149-57
94. Breimer DD, Danhof M. Relevance of the application of pharmacokinetic/pharmacodynamic modelling concepts in drug development: the 'wooden shoe' paradigm. Clin Pharmacokinet 1997; 32: 259-67
95. Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modelling in drug development. Annu Rev Pharmacol Toxicol 2000; 40: 67-95
96. Gieschke R, Steimer JL. Pharmacometrics: modelling and simulation tools to improve decision making in drug development. Eur J Drug Metab Pharmacokinet 2000; 25 (1): 49-58
97. Holford N, Monteleone J, Kimko H, et al. Simulation of clinical trials. Annu Rev Pharmacol Toxicol 2003; 40: 209-34
98. Kaufmann WJ, Smarr LL. Supercomputing and the transformation of science. New York: Scientific American Library, 1993
99. Johnson S. The role of simulation in the management of research: what can the pharmaceutical industry learn from the aerospace industry? Drug Inf J 1998; 32: 961-9
100. Morales Piga A, Abraira Santos V, Rey Rey JS, et al. Factors that determine intensity of response to treatment with tiludronate in Paget's disease [in Spanish]. Med Clin (Barc) 1998; 110 (7): 254-8
101. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001; 28 (6): 507-32
102. Chan PLS, Holford NHG. Drug treatment effects on disease progression. Annu Rev Pharmacol Toxicol 2001; 41: 625-59
103. Hernandez CJ, Beaupre GS, Marcus R, et al. A theoretical analysis of the contributions of remodeling space, mineralization, and bone balance to changes in bone mineral density during alendronate treatment. Bone 2001; 29 (6): 511-6
104. Chavassieux PM, Arlot ME, Wei L, et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997; 100 (6): 1475-80
105. Bauss F, Wagner M, Hothorn L. Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats. J Rheumatol 2002; 29 (5): 990-8
106. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993; 21: 457-79
107. Smolen V. Quantitative determination of drug bioavailability and biokinetic behavior from pharmacological data for ophthalmic and oral administration of a mydriatic drug. J Pharm Sci 1971; 60: 354-63
108. Gabrielsson J, Jusko WJ, Alari L. Modeling of dose-response time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles. Biopharm Drug Dispos 2000; 21: 41-52
109. Jacqmin P, Gieschke R, Jordan P, et al. Modeling drug induced changes in biomarkers without using drug concentrations. Basel: PAGE meeting, 2001 [online]. Available from URL: http://www.page-meeting.org/default.asp?id= 21&keuze=abstract-view&goto=abstracts&orderby=author& abstract_id=232 [Accessed 2005 Jan 13]